Across TCGA pan-cancer cohorts, RIMKLA mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of RIMKLA’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RIMKLA mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RIMKLA is over-expressed in tumor.
CCRCC are the cancer types where RIMKLA tumor–normal differential expression is most reproducible.